# INSTITUTI NAL

# **ITC**

## In-line show; FMCG continues to shine

ITC's 3QFY21 was broadly in line as the company saw sequential recovery across categories. FMCG sustained broad-based double digit growth, and cigarettes continued sequential recovery. Cigarette net revenue/vol/EBIT clocked -8/-7/-8% YoY growth vs. our expectation of -3/-7/-7% growth. Comparable FMCG growth at 11% was ahead of peers like Britannia (6% YoY). Urban growth continued to lag rural for cigarettes, although the product mix improved. Increased mobility of consumers and gradual return to offices will support recovery in cigarettes over the next few months. FMCG continues to shine as new launches and the essentials portfolio maintained its momentum, and ITC continued to capitalise on the high demand for health, hygiene and packaged food products. OOH and discretionary categories are expected to continue the strong growth witnessed in 3QFY21. We remain optimistic on the company's ability to delivery healthy earnings growth and maintain our EPS estimates for FY22/FY23. We value ITC on SoTP to derive a target price of Rs 245 (implied P/E of 18x P/E Mar-23E EPS). Maintain BUY.

- In-line revenue, FMCG outperformance continues: Net revenue grew by 5% YoY (+5% in 3QFY20 and +1% in 2QFY21). Cigarettes saw 4% YoY growth in gross revenue while net revenue declined by 8% YoY, with a volume decline of ~7% (HSIE 7% dip). FMCG/Agri clocked 8/19% YoY growth while Hotels/Paper declined by 57/5% YoY. FMCG clocked 11% growth on a comparable basis. The growth was broad-based across hygiene, packaged foods, discretionary and OOH categories as sentiments improved. FMCG EBITDA margin was at 9.2% (up 140bps YoY). Hotel occupancy improved due to increased mobility of consumers. ITC saw strong growth in Agri driven by trading opportunity in rice, soya and wheat.
- Flat cigarette EBIT margin, strong FMCG margin: GM contracted by 200bps YoY to 60.2% (-23bps in 3QFY20 and -180bps in 2QFY21) vs expectation of 35bps YoY expansion. Employee/other expenses grew by 8/17% YoY. EBITDA margin dipped by 437bps YoY to 34% (+56bps in 3QFY20 and -453bps in 2QFY21) vs expectation of 204bps YoY contraction. EBITDA declined by 7% YoY (HSIE -6%). Cigarettes EBIT declined by 8% while margin was flat YoY after contraction in 1HFY21. FMCG clocked EBIT/EBITDA margin of 5.8/9.2% (28% growth in EBITDA). Hotels clocked an EBIT loss of Rs 673mn (breakeven at EBITDA). High other income restricted the decline in PBT to 4% YoY while APAT was down 3% YoY.
- Other takeaways: (1) Savlon reached Rs 10bn at consumer spends; (2) <u>ITC</u> saw market share gains in cigarettes; (3) e-comm revenue salience stood at 5%; (4) the company expanded its market and outlet coverage to 1.3 and 1.1x of pre-COVID level; (5) hotels reached breakeven at EBITDA level and the company reduced controllable cash costs by 44%; (5) DPS was at Rs 5/share.

Quarterly/Annual Financial summary

YE Mar (Rs mn)	3QFY21	3QFY20	YoY (%)	2QFY21	QoQ (%)	FY20	FY21E	FY22E	FY23E
Net Sales	125,804	120,130	4.7	119,768	5.0	494,041	482,918	546,911	589,080
EBITDA	42,814	46,127	(7.2)	40,606	5.4	192,602	171,009	203,776	218,069
APAT	36,629	37,766	(3.0)	32,324	13.3	152,275	134,346	161,638	172,288
Diluted EPS (Rs)	3.0	3.1	(3.1)	2.6	13.3	12.4	10.9	13.1	14.0
P/E (x)						18.2	20.7	17.2	16.1
EV / EBITDA (x)						12.6	14.1	11.6	10.7
RoCE (%)						45.7	38.6	45.8	47.3

Source: Company, HSIE Research

## BUY

CMP (as on 11	Rs 226		
Target Price		Rs 245	
NIFTY		15,173	
KEY CHANGES	OLD	NEW	
Rating	BUY	BUY	
Price Target	Rs 243	Rs 245	
EDC 0/	FY22E	FY23E	
EPS %	1%	1%	

#### **KEY STOCK DATA**

Bloomberg code	ITC IN
No. of Shares (mn)	12,305
MCap (Rs bn) / (\$ mn)	2,787/38,245
6m avg traded value (Rs mn)	6,863
52 Week high / low	Rs 239/135

#### STOCK PERFORMANCE (%)

	3 <b>M</b>	6M	12M
Absolute (%)	22.2	11.5	6.5
Relative (%)	4.0	(22.6)	(18.5)

#### **SHAREHOLDING PATTERN (%)**

	Sep-20	Dec-20
Promoters	0.00	0.00
FIs & Local MFs	43.54	42.94
FPIs	12.96	13.31
Public & Others	43.50	43.75
Pledged Shares	0.00	0.00
Source : BSE		

Pledged shares as % of total shares

## Varun Lohchab

varun.lohchab@hdfcsec.com +91-22-6171-7334

#### Naveen Trivedi

naveen.trivedi@hdfcsec.com +91-22-6171-7324

## Aditya Sane

aditya.sane@hdfcsec.com +91-22-6171-7336



## **HSIE Results Daily**



#### Disclosure:

Authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. **does not have** any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate **does not have** any material conflict of interest.

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

#### Disclaimer

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066 Compliance Officer: Binkle R. Oza Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

### **HDFC** securities

#### **Institutional Equities**

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013

Board: +91-22-6171-7330 www.hdfcsec.com